Blue Diamond Ventures Inc (BLDV)

[JPS02]

Key highlights of 10/15/18 BLDV PR:

- Although the PR did not seem to have much impact and had spelling mistakes, I think the following two key PR extracts were important in regards to Dharma receiving the Virginia conditional approval before CannX:

1. At the opening reception of the CannX Conference, the acceptence of the Cannareet Product LIne in Virginia was annouced as the latest achivements of Cann10 Israel.

- I think this announcement is key in that it gives Cann10 and BLDV great publicity in front of the 800 conference attendees that attended CannX for their achievements in creating the Cannareet product line and submitting the winning application in Virginia for 1 of 5 winners. I think there must have been questions at the conference on what happened in Virginia and what BLDV's role was. If there were many eyes on BLDV because of the Virginia conditional approval before the conference, there will probably be more eyes on/interest in BLDV now after this announcement at the conference.

2. Dharma Pharmaceuticals will receive final conditional approval in Virginia on the 25th of October and has already requested final terms and conditions from BLDV to supply the Cannareet product line in Virigina.

- With the PR indicating that October 25th is the date for final conditional approval by the Virginia BOP and Dharma requesting final terms and conditions from BLDV to supply Cannareet, the potential to realize revenue from BLDV's efforts may be clearer after October 25th. More importantly, it will be interesting to see how Cannareet enters the North American market and obtains the approvals potentially required - this may be a significant achievement to complete (i.e. FDA, DEA - see my previous post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144206968)

- I believe this will be a significant achievement for BLDV to be an indispensable middle man with a sustainable competitive advantage where Dharma critically needs BLDV to set up the CBD facility and produce Cannareet and Cann10 needs BLDV to serve the Cannareet clients in North America because they cannot come over from Israel every time Dharma or other potential clients need something or an issue has to be addressed. I believe that the conditional approval in Virginia put BLDV on the map in the medical cannabis space in North America. Execution and timely delivery of results will be key for BLDV to accomplish going forward.

- I think that the Virginia conditional approval puts BLDV in a strong position of negotiating leverage with Cann10 for the share exchange agreement and with Dharma and future potential clients in North America to not only prepare the winning application but also set up the facility and produce the required product using the latest Israeli technologies and products in order to realize the maximum investment value of any valuable license approval received. I believe a lot of eyes may be on BLDV right now; therefore, execution and delivery of results will be key for BLDV to accomplish.

Source of PR extracts - BLDV 10/15/18 PR: https://www.otcmarkets.com/stock/BLDV/news?id=206900

Go BLDV!